Cargando…
Prime–boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu(+ )metastatic breast cancer in mice
INTRODUCTION: Once metastasis has occurred, the possibility of completely curing breast cancer is unlikely, particularly for the 30 to 40% of cancers overexpressing the gene for HER2/neu. A vaccine targeting p185, the protein product of the HER2/neu gene, could have therapeutic application by contro...
Autores principales: | Wang, Xiaoyan, Wang, Jian-Ping, Rao, Xiao-Mei, Price, Janet E, Zhou, Heshan S, Lachman, Lawrence B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242122/ https://www.ncbi.nlm.nih.gov/pubmed/16168101 http://dx.doi.org/10.1186/bcr1199 |
Ejemplares similares
-
Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model
por: Eralp, Yesim, et al.
Publicado: (2004) -
Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis
por: Wang, Xiaoyan, et al.
Publicado: (2005) -
Vaccination against Her-2/neu, with focus on peptide-based vaccines
por: Tobias, J., et al.
Publicado: (2022) -
Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates
por: Luo, Shengxue, et al.
Publicado: (2021) -
An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes
por: Khanam, Saima, et al.
Publicado: (2007)